d******l
发帖数: 1952 | 1 Anyone is interesting it @6.5 ?
it seems a good entry point.
target 14, but I don't know how long time to wait.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to
develop, acquire and commercialize, on its own or with partners, a portfolio
of cancer therapies that address unmet medical needs. The Company is
focused on developing products in immuno-oncology that employ gene
expression, control and cell technologies to deliver cell- and viral-based
therapies for the treatment of cancer and graft-versus-host-disease. It has
developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-
tumorally under the control of the RheoSwitch Therapeutic System (RTS)
expression platform. Its initial clinical stage product candidate, which is
being developed using the immuno-oncology platform is Ad-RTS-IL-12 +
veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce
interleukin-12. As of December 31, 2016, it had completed two Phase II
studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic
melanoma and metastatic breast cancer. |
|
